SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

28 Jan 2025 Evaluate
Revenue reduced marginally to stand at Rs. 839.99 millions during the quarter ended December 2024. The figure stood at Rs. 860.69 millions during the year-ago period.The Net Loss for the quarter ended December 2024 is Rs. -11.65 millions as compared to Net Profit of Rs. 46.51 millions of corresponding quarter ended December 2023A decline of 56.86 millions was observed in the OP in the quarter ended December 2024 from 135.22 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202412 202312 % Var 202412 202312 % Var 202403 202303 % Var
Sales 839.99 860.69 -2.41 2587.67 2847.47 -9.12 3786.77 4030.44 -6.05
Other Income 0.40 12.09 -96.69 22.66 29.80 -23.96 75.08 56.78 32.23
PBIDT 56.86 135.22 -57.95 202.07 556.47 -63.69 743.73 603.56 23.22
Interest 4.16 3.77 10.34 9.02 62.89 -85.66 65.07 83.84 -22.39
PBDT 52.70 131.45 -59.91 193.05 493.58 -60.89 678.66 483.85 40.26
Depreciation 69.23 65.82 5.18 203.98 193.69 5.31 256.01 95.54 167.96
PBT -16.53 65.63 -125.19 -10.93 299.89 -103.64 422.65 388.31 8.84
TAX -4.88 19.12 -125.52 -3.25 88.87 -103.66 129.17 -16.34 -890.51
Deferred Tax -4.32 5.91 -173.10 -3.41 36.70 -109.29 55.74 -35.93 -255.13
PAT -11.65 46.51 -125.05 -7.68 211.02 -103.64 293.48 404.65 -27.47
Equity 233.92 233.92 0.00 233.92 233.92 0.00 233.92 221.65 5.54
PBIDTM(%) 6.77 15.71 -56.91 7.81 19.54 -60.04 19.64 14.98 31.15

Tatva Chintan Pharma Share Price

1275.10 -8.55 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3703.10
Tata Chemicals 709.05
SRF 2493.65
Pidilite Inds. 1393.25
Deepak Nitrite 1538.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×